SARMs vs. AAS: Harm Reduction Comparison

Selective Androgen Receptor Modulators (SARMs) are often marketed as a “safer alternative” to anabolic-androgenic steroids (AAS). The reality is more nuanced.

Pharmacokinetic differences

Most SARMs are oral with short half-lives (hours to ~1 day), whereas most AAS are injectable esters with half-lives of days to weeks. This means SARMs clear quickly — convenient, but also meaning any side effects resolve faster once stopped.

Suppression

Contrary to marketing, many SARMs are suppressive. Ligandrol (LGD-4033) and Testolone (RAD-140) can suppress endogenous testosterone meaningfully at typical doses, often warranting a mini-PCT.

Liver

SARMs are orally active and undergo first-pass metabolism. Mild hepatic stress is reported; severe hepatotoxicity is rare but documented with contaminated or mislabeled products.

Bottom line

SARMs are not risk-free, and they are not AAS. Treat them with the same respect for bloodwork, source quality, and post-cycle recovery.